CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.
CAR-T cell
CRISPR/Cas9
cancer
clinical application
gene editing
immunotherapy
Journal
Briefings in functional genomics
ISSN: 2041-2657
Titre abrégé: Brief Funct Genomics
Pays: England
ID NLM: 101528229
Informations de publication
Date de publication:
20 05 2020
20 05 2020
Historique:
received:
30
09
2019
revised:
04
11
2019
accepted:
22
11
2019
pubmed:
18
12
2019
medline:
20
7
2021
entrez:
18
12
2019
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR)-modified T cells have raised among other immunotherapies for cancer treatment, being implemented against B-cell malignancies. Despite the promising outcomes of this innovative technology, CAR-T cells are not exempt from limitations that must yet to be overcome in order to provide reliable and more efficient treatments against other types of cancer. The purpose of this review is to shed light on the field of CAR-T cell gene editing for therapy universalization and further enhancement of antitumor function. Several studies have proven that the disruption of certain key genes is essential to boost immunosuppressive resistance, prevention of fratricide, and clinical safety. Due to its unparalleled simplicity, feasibility to edit multiple gene targets simultaneously, and affordability, CRISPR/CRISPR-associated protein 9 system has been proposed in different clinical trials for such CAR-T cell improvement. The combination of such powerful technologies is expected to provide a new generation of CAR-T cell-based immunotherapies for clinical application.
Identifiants
pubmed: 31844895
pii: 5675469
doi: 10.1093/bfgp/elz039
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-200Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.